208
Participants
Start Date
July 31, 2009
Primary Completion Date
September 30, 2010
LX3305 low dose
A low dose of LX3305; daily oral intake for 12 weeks
LX3305 mid dose
A mid dose of LX3305; daily oral intake for 12 weeks
LX3305 high dose
A high dose of LX3305; daily oral intake for 12 weeks
Placebo
Matching placebo dosing with daily oral intake for 12 weeks
Lexicon Investigational Site, Philadelphia
Lexicon Investigational Site, Cumberland
Lexicon Investigational Site, Hagerstown
Lexicon Investigational Site, Hickory
Lexicon Investigational Site, Orange Park
Lexicon Investigational Site, Gainesville
Lexicon Investigational Site, Orlando
Lexicon Investigational Site, Tampa
Lexicon Investigational Site, Nashville
Lexicon Investigational Site, Flowood
Lexicon Investigational Site, Kalamazoo
Lexicon Investigational Site, La Crosse
Lexicon Investigational Site, Dallas
Lexicon Investigational Site, Pleven
Lexicon Investigational Site, Plovdiv
Lexicon Investigational Site, Rousse
Lexicon Investigational Site, Sofia
Lexicon Investigational Site, Veliko Tarnovo
Lexicon Investigational Site, Bruntál
Lexicon Investigational Site, Hlučín
Lexicon Investigational Site, Sokolov
Lexicon Investigational Site, Zlín
Lexicon Investigational Site, Békéscsaba
Lexicon Investigational Site, Budapest
Lexicon Investigational Site, Kecskemét
Lexicon Investigational Site, Makó
Lexicon Investigational Site, Sopron
Lexicon Investigational Site, Veszprém
Lexicon Investigational Site, Bialystok
Lexicon Investigational Site, Działdowo
Lexicon Investigational Site, Gdynia
Lexicon Investigational Site, Katowice
Lexicon Investigational Site, Lublin
Lexicon Investigational Site, Warsaw
Lexicon Investigational Site, Wroclaw
Lexicon Investigational Site, Włoszczowa
Lexicon Investigational Site, Belgrade
Lexicon Investigational Site, Niška Banja
Lead Sponsor
Lexicon Pharmaceuticals
INDUSTRY